3 Pharmaceutical Stocks to Sell Now

Advertisement

The overall ratings of three pharmaceutical stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Lipocine, Inc.’s (LPCN) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. In Portfolio Grader’s specific subcategories of Earnings Revisions, Equity and Cash Flow, LPCN also gets an F. To get an in-depth look at LPCN, get Portfolio Grader’s complete analysis of LPCN stock.

This week, Alimera Sciences, Inc. (ALIM) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Alimera Sciences engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The stock also rates an F in Cash Flow. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of ALIM stock.

Perrigo Co. Plc (PRGO) earns a D this week, moving down from last week’s grade of C. The Perrigo manufactures, distributes and markets pharmaceutical and nutritional products. The stock has a trailing PE Ratio of 57.00. To get an in-depth look at PRGO, get Portfolio Grader’s complete analysis of PRGO stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/03/3-pharmaceutical-stocks-to-sell-now-lpcn-alim-prgo-2/.

©2024 InvestorPlace Media, LLC